Ozempic reaches most people through the weight-loss conversation, though its FDA label is for type 2 diabetes. This page separates mechanism from marketing: how semaglutide acts at the GLP-1 receptor, what the published trials report, and the genetics beneath it all.

Wegovy is semaglutide, a GLP-1 receptor agonist studied for chronic weight management. This page explains the appetite-and-glucose mechanism, what the STEP trial program reported, the FDA label limits, key safety signals, and how your genetic starting point fits the conversation.

A GLP-1 receptor agonist is a medication that reproduces the effects of the GLP-1 hormone. This guide explains what the class is, how it works, which compounds are FDA-approved as of April 2026, and the genetic variables that sit upstream of every GLP-1 decision.

This overview focuses on the injectable form of semaglutide for weight management, from its GLP-1 mechanism and the SUSTAIN, STEP, and PIONEER evidence to approvals, contraindications, and the inherited variants that shape metabolism. Every figure stays anchored to published labeling and literature.

GLP-1 receptor agonists have reshaped the way people talk about weight management. This overview explains the mechanism in plain terms, walks through the major trial programs and their reported effect sizes, traces the approval timeline, flags the key limitations, and shows how inherited traits shape the metabolic picture.

Here is the catch most Wegovy-versus-Ozempic searches miss: both are the same molecule, semaglutide, sold under two brand names. This independent review explains where dose, indication, price, and coverage actually diverge, and why the underlying genetics stay identical no matter which label you fill.

The GLP-1 medication category has grown quickly and can be hard to keep straight. This roster explains what the hormone is, how the receptor-agonist class works, which compounds are FDA-approved as of April 2026, and the inherited variables that sit beneath the pathway.

Ozempic and Wegovy share one molecule, semaglutide, but carry different FDA indications and doses. This independent review explains why the underlying pharmacology stays identical while the labels, trial programs, list price, and appetite genetics that shape each decision are what actually set them apart.

GLP-1 drugs are engineered from a natural gut hormone that resists rapid breakdown. This article traces the biology, explains how the receptor agonist class works, lists the FDA-approved and investigational compounds as of April 2026, and covers the genetics sitting upstream.

GLP-1 was a gut hormone long before it was a medication. This PlexusDx explainer defines glucagon-like peptide-1, follows its actions, explains why it was engineered into a drug class, lists the approved compounds, and turns to the GLP1R pathway underneath.

Genetic testing doesn't treat sexual dysfunction — it maps the biological terrain that every treatment decision operates within. The Precision Peptide Genetic Test delivers 6 Sexual Health insights across 14 pathways, 49 peptides, and 150+ genetic insights, giving providers the upstream biological context that bloodwork alone cannot supply — and changing the clinical conversation before any protocol begins.

In the Precision Peptide Genetic Test, the Sexual Health pathway delivers 6 insights across the genes governing central arousal, vascular sexual response, desire, bonding, and circadian sexual timing. Part of 14 pathways, 49 peptides, and 150+ genetic insights, these 6 variants map sexual biology as a connected system — not a checklist of isolated traits.

PDE5 pathway support compounds work differently for different men because the upstream signal they amplify — eNOS-derived nitric oxide — is genetically variable. NOS3 genotype sets the vascular floor. The Precision Peptide Genetic Test maps this and other pathway variables across 14 pathways, 49 peptides, and 150+ genetic insights, explaining the response variability that dosing alone cannot.

Libido has a genetic architecture — DRD2 receptor density, OXTR bonding sensitivity, MTNR1B circadian timing, and MC4R central arousal signaling all shape sexual desire at the neurochemical level. The Precision Peptide Genetic Test maps these variables as part of 14 pathways, 49 peptides, and 150+ genetic insights, explaining the biology of desire that testosterone panels miss.

Erectile function depends on multiple gene-governed systems — nitric oxide production, central arousal signaling, dopamine-driven desire, and cGMP preservation. The Precision Peptide Genetic Test maps the key variants across 14 pathways, 49 peptides, and 150+ genetic insights, identifying the genetic architecture that testosterone panels and vascular tests alone cannot reveal.

Sexual wellness has a genetic architecture — six biological variables that determine how your body produces arousal, routes blood flow, generates desire, and responds to intimacy. The Precision Peptide Genetic Test maps all six as part of 14 pathways, 49 peptides, and 150+ genetic insights, answering the question that hormone panels and bloodwork alone cannot.

Central sexual arousal — the brain-driven signal that initiates the entire sexual response cascade — runs through the melanocortin pathway and its primary receptor, MC4R. The Precision Peptide Genetic Test analyzes melanocortin pathway variants as part of 14 pathways, 49 peptides, and 150+ genetic insights, mapping the CNS architecture of arousal that vascular testing cannot reach.

The PlexusDx Precision Peptide Genetic Test analyzes 34 weight management genetic insights — covering 8 peptide pathways, 11 SNPs, and 9 genes including FTO, MC4R, PPARG, TCF7L2, and GIPR. This comprehensive guide explains what each insight cluster covers, which peptide pathways are analyzed, and why genetic specificity is the missing variable in most weight management decisions.

The PlexusDx Precision Peptide Genetic Test analyzes 34 weight management genetic insights — including the pathways most relevant to GLP-1 receptor signaling. This article explains what the research shows about genetics and semaglutide response, why MTHFR methylation status matters in the broader metabolic picture, and how genetic testing can help inform a smarter weight management approach.

The PlexusDx Precision Peptide Genetic Test analyzes 34 weight management genetic insights — including GLP-1 receptor signaling and GIPR response pathways. This article explains how genes like FTO, MC4R, and PPARG influence appetite, fat metabolism, and weight regulation, and why your DNA may be the most underused variable in any weight management decision.